Ocrelizumab Given Under the Skin for People With Multiple Sclerosis Switching Treatments
Tests ocrelizumab given under the skin in adults with multiple sclerosis switching therapies.
Plain-language title generated from the registry record
Registry title: A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy
Key facts
- Where
- Guaynabo, Puerto RicoSee the site
- Phase
- Phase 4
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07609719, who can take part
Where in Puerto Rico
- Caribbean Center for Clinical ResearchGuaynabo, Puerto RicoTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Genentech, Inc.
- Trial code
- NCT07609719
- Record updated
- 30 October 2026
- Original description
The purpose of this study is to assess the imaging biomarkers, patient outcomes, safety, tolerability, and treatment satisfaction of ocrelizumab (OCR) combined with recombinant human hyaluronidase (rHuPH20) administered subcutaneously (SC) in participants with relapsing multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS) after switching from another anti-cluster of differentiation 20 (aCD20) therapy approved for RMS (ofatumumab SC, ublituximab-xiiy intravenous [IV], ocrelizumab IV) or PPMS (ocrelizumab IV).Read full original descriptionShow less
A Prospective, Multicenter, Single-arm Study of Ocrelizumab Administered Subcutaneously in Patients With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy
The purpose of this study is to assess the imaging biomarkers, patient outcomes, safety, tolerability, and treatment satisfaction of ocrelizumab (OCR) combined with recombinant human hyaluronidase (rHuPH20) administered subcutaneously (SC) in participants with relapsing multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS) after switching from another anti-cluster of differentiation 20 (aCD20) therapy approved for RMS (ofatumumab SC, ublituximab-xiiy intravenous [IV], ocrelizumab IV) or PPMS (ocrelizumab IV).
Inclusion: Diagnosis of RMS or PPMS according to the revised McDonald 2017 criteria; Documented Expanded Disability Status Scale (EDSS) score of 0-6.5, inclusive, at screening (or within 6 months of screening); Participants discontinuing aCD20 therapy for reasons including, but not limited to, physician/participant preference, access to commercial drug (e.g., insurance coverage issues), or other logistical reasons (such as geographical relocation, travel, etc.) are eligible for this study; Prior treatment with ofatumumab SC, ublituximab-xiiy IV, or ocrelizumab IV aCD20 therapy.
Exclusion: Participants who have demonstrated suboptimal response to aCD20 therapy; Discontinuing aCD20 therapy because of any of the following treatment emergent adverse events (TEAEs): 1) Grade ≥3 severe infusion-related reaction (IRRs) or injection reactions (IRs); 2) Recurrent Grade ≥3 infections, or the need for ≥2 courses of antibiotics in the 12 months prior to screening, if the investigator believes infection is related to therapy; Any concomitant disease that may require treatment with systemic corticosteroids (e.g., mineralocorticoids and glucocorticoids) or immunosuppressants during the study; Any previous treatment with bone marrow transplantation and hematopoietic stem cell transplantation; Treatment with any live-attenuated vaccine within 6 weeks prior to baseline; Treatment with any experimental procedures for RMS or PPMS (e.g., treatment for chronic cerebrospinal venous insufficiency); Previous treatment with cladribine, atacicept, alemtuzumab or mitoxantrone; Known presence of active, recurrent, or chronic infection (e.g., human immunodeficiency virus [HIV], syphilis, human papillomavirus [HPV], tuberculosis [TB]); History of confirmed or suspected progressive multifocal leukoencephalopathy (PML); Known presence of neurologic disorders that may interfere with the diagnosis of RMS or PPMS; Known allergy or hypersensitivity to ocrelizumab, rHuPH20, or excipients of the OCR SC formulation; Positive hepatitis B virus (HBV) and hepatitis C virus (HCV) antibody test at screening; Other protocol defined inclusion and exclusion criteria may apply; Participants with contraindication to Gd+ and participants who for any reason cannot tolerate MRI procedure.